The continued quest for an 'ideal anticoagulant' led to the US ... a Factor Xa inhibitor (Xarelto®) and apixaban (Eliquis®, Bristol-Myers Squibb and Pfizer) for various specified indications.

Conclusion Apixaban, a new anticoagulant, appears to offer an efficacy and safety profile comparable with that of enoxaparin for preventing VTE after orthopedic surgery, with the advantage of oral ...

Two common medications that are categorized as blood thinners and used to prevent blood clots are anticoagulants and antiplatelets. Both are essential in treating conditions caused by blood clots ...

New data from a clinical trial suggest that apixaban, an anticoagulant that’s widely been prescribed to promote recovery in patients with severe cases of COVID-19, doesn’t offer any discernable ...

Apixaban is an anticoagulant, which is used for reducing the risk of strokes and blood clots in patients with atrial fibrillation who have no problems with their heart valve (nonvalvular atrial ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

According to IQVIA, the global market for anticoagulants is rapidly expanding, with apixaban achieving U.S. sales of $22.1 billion in 2023, making it the leading small-molecule drug globally and ...

TAIPEI, Jan. 21, 2025 /PRNewswire/ -- TAHO Pharmaceuticals is pleased to announce the successful completion of the pivotal trial for TAH3311, the first anticoagulant oral dissolving film (ODF).